GSK plc (GLAXF)
| Market Cap | 108.78B +34.3% |
| Revenue (ttm) | 43.97B +4.1% |
| Net Income | 7.69B +122.0% |
| EPS | 1.87 +123.2% |
| Shares Out | n/a |
| PE Ratio | 14.14 |
| Forward PE | 11.51 |
| Dividend | 0.88 (3.24%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 507 |
| Average Volume | 2,779 |
| Open | 30.15 |
| Previous Close | 27.25 |
| Day's Range | 27.25 - 30.15 |
| 52-Week Range | 15.54 - 31.48 |
| Beta | 0.32 |
| RSI | 61.43 |
| Earnings Date | Apr 29, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK Achieves Approval in China for Asthma Treatment Exdensur
GSK Achieves Approval in China for Asthma Treatment Exdensur
GSK (GSK) Seeks Chinese Approval for New Hepatitis B Treatment
GSK (GSK) Seeks Chinese Approval for New Hepatitis B Treatment
Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.
Technical indicators for Pfizer and GSK have turned bullish.
GSK Announces Approval For Exdensur In China
(RTTNews) - GSK plc (GSK, GSK.L) announced that China's National Medical Products Administration has approved Exdensur or depemokimab as add-on maintenance treatment of severe asthma characterised by ...
GSK: European Medicines Agency To Review MAA For Bepirovirsen
(RTTNews) - GSK plc (GSK, GSK.L) announced that the European Medicines Agency has accepted for review the marketing authorisation application for the use of bepirovirsen, an investigational antisense ...
GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript
GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript
GSK PLC (GSK) Stock Price Up 3.7% on Mar 25
GSK PLC (GSK) Stock Price Up 3.7% on Mar 25
Clover Biopharmaceuticals Reports Positive U.S. Phase I Data On RSV Re-Vaccination In Older Adults
(RTTNews) - Clover Biopharmaceuticals, Ltd. (2197.HK) announced new Phase I clinical trial results from the U.S. evaluating re-vaccination with its RSV PreF vaccine candidate (SCB-1019) compared head-...
GSK (GSK) Antibody-Drug Conjugate Gains Orphan Drug Status in Japan
GSK (GSK) Antibody-Drug Conjugate Gains Orphan Drug Status in Japan
Dividend Income: Lanny's January 2026 Summary
Dividend income is the fruit from the labor of investing your money in the stock market. The power of compounding and dividend reinvestment is a wonderful component of the portfolio. In total, dividen...
Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal
(RTTNews) - This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic a...
GSK Secures FDA Approval for Lynavoy in Treating PBC-Related Itch
GSK Secures FDA Approval for Lynavoy in Treating PBC-Related Itch
US FDA approves GSK's drug for liver disease related itching
The U.S. Food and Drug Administration approved GSK's drug for severe relentless itching caused by a type of liver disease, the company said on Thursday, making it the first treatment greenl...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
GSK, with Luke Miels becoming its new CEO in early 2026, continues its successful expansion into the oncology and cardiovascular drugs markets. So, on February 25, GSK announced that it acquired 35Pha...
Myriad Genetics Gains FDA Nod For Ovarian Cancer Test
(RTTNews) - Myriad Genetics, Inc., (MYGN) announced that the U.S. FDA has approved its MyChoice CDx Test as the companion diagnostic for Zejula, a PARP inhibitor developed by GSK, for patients with ad...
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs. T...
Amgen (AMGN) and GSK (GSK) Expand Reach with TrumpRx Partnership
Amgen (AMGN) and GSK (GSK) Expand Reach with TrumpRx Partnership
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
GSK and Amgen will add their medicines to TrumpRX, the prescription drug website launched by President Donald Trump's administration, Fox Business reported on Friday.
FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults
On Friday, the U.S. Food and Drug Administration (FDA) expanded the approved age indication for GSK plc’s (NYSE: GSK) respiratory syncytial virus vaccine, Arexvy. The approval allows its use in adult...
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
PHILADELPHIA--(BUSINESS WIRE)--GSK's RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk.
GSK Says FDA Expands Arexvy RSV Vaccine Approved Age To Adults 18 To 49 Years At Increased Risk
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration or FDA, has expanded the approved age indication of Arexvy (Respiratory Syncytial Virus va...
GSK gets US FDA approval for expanded use of RSV vaccine
British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age range for its respiratory syncytial virus vaccine, Arexvy, to include adults aged 18 to 49 wh...
BioVersys Doses First Patient In Phase 2b Of AlpE
(RTTNews) - BioVersys AG (BIOV) has announced that the first patient has been dosed in its Phase 2b clinical trial of AlpE for pulmonary tuberculosis, marking a key milestone in the company's collabor...
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript